×
Codexis Net Current Debt 2010-2025 | CDXS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Codexis net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Codexis Net Current Debt 2010-2025 | CDXS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Codexis net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.5B
Amgen (AMGN)
$159.7B
Gilead Sciences (GILD)
$139.4B
Vertex Pharmaceuticals (VRTX)
$121.3B
Bristol Myers Squibb (BMY)
$96.3B
GSK (GSK)
$78.4B
CSL (CSLLY)
$77.4B
Regeneron Pharmaceuticals (REGN)
$61.6B
Alnylam Pharmaceuticals (ALNY)
$41.2B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$20.4B
Biogen (BIIB)
$19.5B
Insmed (INSM)
$19.3B
Illumina (ILMN)
$15.6B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.8B
Incyte (INCY)
$13.5B
Moderna (MRNA)
$12.7B
Exelixis (EXEL)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.4B
Bio-Techne Corp (TECH)
$8.2B
Roivant Sciences (ROIV)
$7.9B
Regencell Bioscience Holdings (RGC)
$7.3B